- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Cytolon Partners with iSoft for New Life Science Research Tool
Berlin, December 16th 2010 - Cytolon AG announced today the signing of an agreement with iSoft to integrate its AccelFind solution, developed by US-based CliniWorks, with its platform CordMatch®. CordMatch® is a unique, web-based platform that integrates product search and matching-to-patient, logistics, billing and follow-up for the matching of stem cell products. The integration will provide additional advantages to CordMatch® allowing the secondary use of electronic health records, offering a whole new world of possibilities for clinical development, adding value for pharmaceutical companies and permitting ultimately the improvement of therapy quality and fostering personalized medicine.
Thomas Klein, founder and CEO of Cytolon AG, stated, “We are very pleased to be able to integrate AccelFind to CordMatch®. The integration allows extracting medical knowledge from any type of data, like electronic medical records or laboratory systems, promoting knowledge collaboration for highly efficient clinical research, outcomes tracking and management.”
iSOFT’s Director for Life Sciences, Dr. Joerg Kraenzlein, said: “This is a tremendous opportunity to accelerate clinical research in a so far unprecedented way, and tap into new areas of treatment options and value propositions that have the potential to change the way we perform medicine and use healthcare IT today.”
About Cytolon AG:
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area. For more information, please visit the company's Web site at www.cytolon.com.
About iSOFT Group:
iSOFT Group Limited (ASX: ISF) is the largest health information technology company listed on the Australian Securities Exchange, and among the world’s biggest providers of advanced application solutions in modern healthcare economies. iSOFT works with healthcare professionals to design and build software applications that answer all of the difficult questions posed by today’s healthcare delivery challenges. Our solutions act as a catalyst for change, supporting free exchange of critical information across diverse care settings and participating organizations. Today, more than 13,000 provider organizations in over 40 countries use iSOFT’s solutions to manage patient information and drive improvements in their core processes. The group’s sustainable development is delivered through careful planning, in-depth analysis of the market, and anticipation of our clients’ evolving requirements. Our business is driven by the collective talent, experience and commitment of more than 3,500 specialists in 19 countries worldwide.
A global network of iSOFT subsidiaries, supported by an extensive partner network, provides substantial experience of national healthcare markets. As a result, we offer our clients comprehensive knowledge of local market requirements in terms of culture, language, working practices, regulation and organizational structure. www.isofthealth.com
Contact:
Nina Hofle - PR
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 2880
fax: +49 (0) 30 2639 28820
e-mail: info@cytolon.com
web: www.cytolon.com